Cargando…

Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential

PReferentially expressed Antigen in Melanoma (PRAME) is a cancer testis antigen with restricted expression in somatic tissues and re‐expression in poor prognostic solid tumours. PRAME has been extensively investigated as a target for immunotherapy, however, its role in modulating the anti‐tumour imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naik, Adviti, Thomas, Remy, Al‐Khadairi, Ghaneya, Bacha, Rim, Hendrickx, Wouter, Decock, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581324/ https://www.ncbi.nlm.nih.gov/pubmed/34612587 http://dx.doi.org/10.1111/jcmm.16967

Ejemplares similares

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

Editorial: Cancer testis antigens in cancer: Recent developments as cancer biomarkers and therapeutic targets
por: Naik, Adviti, et al.
Publicado: (2022)

Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?
por: Hendrickx, Wouter, et al.
Publicado: (2015)

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer
por: Xu, Yichi, et al.
Publicado: (2020)

Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy
por: Naik, Adviti, et al.
Publicado: (2021)

Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma
por: Albertsmeier, Markus, et al.
Publicado: (2020)

Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors
por: Naik, Adviti, et al.
Publicado: (2020)

The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer
por: Naik, Adviti, et al.
Publicado: (2019)

Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
por: Thomas, Remy, et al.
Publicado: (2020)

Commentary: Cancer-testis antigen lactate dehydrogenase C4 as a novel biomarker of male infertility and cancer
por: Naik, A., et al.
Publicado: (2023)

The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas
por: Nettersheim, Daniel, et al.
Publicado: (2016)

Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
por: Iura, Kunio, et al.
Publicado: (2015)

Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder
por: Hodgson, Anjelica, et al.
Publicado: (2019)

Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting
por: Sherif, Shimaa, et al.
Publicado: (2022)

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
por: Raynaud, Christophe Michel, et al.
Publicado: (2023)

Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2(Prame) complex
por: Zhang, Wenjuan, et al.
Publicado: (2021)

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors
por: Gérard, Catherine, et al.
Publicado: (2015)

PRAME expression and clinical outcome of breast cancer
por: Epping, M T, et al.
Publicado: (2008)

PRAME expression and promoter hypomethylation in epithelial ovarian cancer
por: Zhang, Wa, et al.
Publicado: (2016)

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

Pattern of cancer/testis antigen expression in lung cancer patients
por: KIM, YEONG-DAE, et al.
Publicado: (2012)

The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy
por: Bedognetti, Davide, et al.
Publicado: (2017)

Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis
por: Islam, Zeyaul, et al.
Publicado: (2021)

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)
por: Pankov, Dmitry, et al.
Publicado: (2017)

Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma
por: Takata, Katsuyoshi, et al.
Publicado: (2022)

Cancer testis antigen and immunotherapy
por: Krishnadas, Deepa Kolaseri, et al.
Publicado: (2013)

Targeting cancer testis antigens in synovial sarcoma
por: Mitchell, Geoffrey, et al.
Publicado: (2021)

Selenium Biomarkers in Prostate Cancer Cell Lines and Influence of Selenium on Invasive Potential of PC3 Cells
por: Hendrickx, Wouter, et al.
Publicado: (2013)

HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME)
por: Grillini, Marco, et al.
Publicado: (2022)

The Expansion of the PRAME Gene Family in Eutheria
por: Chang, Ti-Cheng, et al.
Publicado: (2011)

Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study
por: Cazzato, Gerardo, et al.
Publicado: (2022)

Sensitive Immunofluorescent Detection of the PRAME Antigen Using a Practical Antibody Conjugation Approach
por: Sapozhnikova, Ksenia A., et al.
Publicado: (2021)

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
por: Luk, Sietse J, et al.
Publicado: (2018)

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
por: Roszik, Jason, et al.
Publicado: (2017)

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas
por: Bui, Chau M., et al.
Publicado: (2021)

PRAME expression is similar in scar and desmoplastic melanoma
por: Plotzke, Jaclyn M., et al.
Publicado: (2022)

PRAME induces genomic instability in uveal melanoma
por: Kurtenbach, Stefan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d31jslhuekgc33br1m97c1lbgr